Development of a vaccine for toxoplasmosis: current status

Bhopale, G. M.

doi:10.1016/s1286-4579(03)00048-0

Cited by 109 publications

(59 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have shown that rhoptry proteins (ROPs) represent potential vaccine candidates against toxoplasmosis, especially the ROP2 protein family (Bhopale, 2003;Dlugonska, 2008;Kur et al, 2009). Sequence variation in different ROP genes is usually low, e.g., 1.7% in ROP7 and 2.0% in ROP13 (Wang et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii rhoptry protein 38 gene: sequence variation among isolates from different hosts and geographical locations

Zhang

Chen

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Toxoplasma gondii is an obligate intracellular parasite that is able to infect almost all mammalian species, and may lead to toxoplasmosis of the host. In the present study, we examined sequence variation in rhoptry protein 38 (ROP38) genes among T. gondii isolates collected from different hosts and geographical regions. The complete ROP38 gene from 13 T. gondii isolates was amplified and sequenced. The results of sequence alignments showed that the lengths of the entire ROP38 gene ranged from 2646 to 2650 bp, with a sequence variation of 0.2-1.1%, among the 13 T. gondii isolates. This result indicated low sequence variation in the ROP38 gene. Phylogenetic analysis of ROP38 sequences using Bayesian inference showed that the clustering of the 13 T. gondii isolates was not consistent with their respective genotypes. This result indicates that the ROP38 gene is not a suitable genetic marker for population genetic studies of different T. gondii genotypes from different hosts and geographical locations, but may represent a potential vaccine candidate against toxoplasmosis, and hence worthy of further research.

show abstract

Section: Introductionmentioning

confidence: 99%

Toxoplasma gondii rhoptry protein 38 gene: sequence variation among isolates from different hosts and geographical locations

Zhang

Chen

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

show abstract

“…To date, the only commercial vaccine, which has been developed using live tachyzoites from the S48 T. gondii strain, is used for protection against toxoplasmosis in sheep [53]. The vaccine is not widely used as a consequence of reactivation of the live tachyzoites to the pathogenic form, short shelf life, and high cost [6]. To circumvent the negative features, current research is focused on developing safe vaccines from DNA segments or from antigenic protein(s) of T. gondii.…”

Section: Discussionmentioning

confidence: 99%

“…Many attempts have been made to create an immunogenic protective vaccine against toxoplasmosis using mutant T. gondii strains, purified proteins, and DNA vaccines since 1990s [6]. The accumulated results suggest that a protective vaccine against T. gondii infection is feasible.…”

Section: Introductionmentioning

confidence: 99%

GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine

Döşkaya

Kalantari-Dehaghi

Walsh

et al. 2007

Vaccine

View full text Add to dashboard Cite

The present study evaluates immunogenicity and protection potency of a codon-optimized GRA1 DNA vaccine, wild type GRA1 DNA vaccine and an adjuvanted recombinant GRA1 protein vaccine candidate in BALB/c mice against lethal toxoplasmosis. Of the three GRA1 vaccines tested, the recombinant GRA1 protein vaccine results reveal significant increase in immune response and prolonged survival against acute toxoplasmosis compared to DNA vaccinations. Immune response and protection conferred by codon-optimized GRA1 DNA vaccine was slightly better than wild type GRA1 DNA vaccine.

show abstract

“…4,5 Treatment of toxoplasmosis is difficult caused by toxic effects of the drugs and possible reinfection. 6 Vaccination is considered the most potent and effective means of fighting the infection. 7 By far the only existing vaccine for toxoplasmosis is the live, attenuated formulation using T. gondii S48 strain.…”

Section: Introductionmentioning

confidence: 99%

Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of Toxoplasma gondii

Parthasarathy¹,

Fong²,

Kalyanasundaram

et al. 2013

The American Society of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Abstract. Toxoplasmosis in humans and other animals is caused by the protozoan parasite Toxoplasma gondii. During the process of host cell invasion and parasitophorous vacuole formation by the tachyzoites, the parasite secretes Rhoptry protein 8 (ROP8), an apical secretory organelle. Thus, ROP8 is an important protein for the pathogenesis of T. gondii. The ROP8 DNA was constructed into a pVAX-1 vaccine vector and used for immunizing BALB/c mice. Immunized mice developed immune response characterized by significant antibody responses, antigen-specific proliferation of spleen cells, and production of high levels of IFN-γ (816 ± 26.3 pg/mL). Challenge experiments showed significant levels of increase in the survival period (29 days compared with 9 days in control) in ROP8 DNA vaccinated mice after a lethal challenge with T. gondii. Results presented in this study suggest that ROP8 DNA is a promising and potential vaccine candidate against toxoplasmosis.

show abstract

Development of a vaccine for toxoplasmosis: current status

Cited by 109 publications

References 56 publications

Toxoplasma gondii rhoptry protein 38 gene: sequence variation among isolates from different hosts and geographical locations

Toxoplasma gondii rhoptry protein 38 gene: sequence variation among isolates from different hosts and geographical locations

GRA1 protein vaccine confers better immune response compared to codon-optimized GRA1 DNA vaccine

Protective Immune Response in BALB/c Mice Induced by DNA Vaccine of the ROP8 gene of Toxoplasma gondii

Contact Info

Product

Resources

About